申请人:PFIZER INC.
公开号:EP0079675A1
公开(公告)日:1983-05-25
A series of novel spiro-oxindole oxazolidinedione derivatives have been prepared, including their base salts with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Preferred compounds include 1-(p-fluorophenyl)-5-fluoro-spiro-[indoline-3,5'-oxazolidine]-2,2',4'-trione, 1-methyl-5-chloro- spiro-[indoline-3,5'-oxazolidine]-2,2',4'-trione, 1-isopropyl-5-chloro-spiro-[indoline-3,5'-oxazolidine]-2,2',4'-trione and 1-(p-chlorobenzyl)-5-chloro-spiro-[indoline-3,5'-oxazolidine]-2,2'-4'-trione. Methods for preparing these compounds from known starting materials are provided.
我们制备了一系列新型螺吲哚噁唑烷二酮衍生物,包括它们与药理学上可接受的阳离子的基盐。这些化合物可作为醛糖还原酶抑制剂用于治疗,以控制某些慢性糖尿病并发症。首选化合物包括 1-(对氟苯基)-5-氟-螺-[吲哚啉-3,5'-恶唑烷]-2,2',4'-三酮、1-甲基-5-氯-螺-[吲哚啉-3,5'-恶唑烷]-2,2'、4'-三酮、1-异丙基-5-氯螺-[吲哚啉-3,5'-恶唑烷]-2,2',4'-三酮和 1-(对氯苄基)-5-氯螺-[吲哚啉-3,5'-恶唑烷]-2,2'-4'-三酮。提供了从已知起始材料制备这些化合物的方法。